Literature DB >> 17143508

Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines.

Marie-Hélène Benoît1, Thomas J Hudson, Georges Maire, Jeremy A Squire, Suzanna L Arcand, Diane Provencher, Anne-Marie Mes-Masson, Patricia N Tonin.   

Abstract

The interpretation of loss of heterozygosity (LOH) in cancers is complicated as genes that map to LOH regions may be transcriptionally active (Xa) or inactive (Xi) due to X chromosome inactivation (XCI). We have analyzed the chromosome X transcriptome in four epithelial ovarian cancer (EOC) cell lines (TOV21G, TOV81D, TOV112D, and OV90) and 12 primary cultures of normal ovarian surface epithelial (NOSE) cells in relation to chromosome X integrity. Two-way comparative analysis using HuGeneFL Affymetrix GeneChips of TOV21G, TOV81D and OV90 relative to the NOSE samples was highly correlated (> 89%) in contrast to that of TOV112D (56-69%). TOV112D, followed by TOV21G, exhibited the largest number of up-regulated genes. XIST expression by RT-PCR was not detectable in TOV112D or TOV21G. Allele-specific transcription by cDNA sequence analysis of genes known to be subjected to XCI revealed maintenance of XCI in TOV81D and OV90, but not TOV21G. Biallelic expression could not be assessed in TOV112D due to reduction to hemizygosity of chromosome X. Chromosome X rearrangements were observed in FISH analysis of TOV112D and TOV21G, and both of these EOC cell lines were negative for Barr body analysis. The differentially expressed genes did not appear to map to any particular region of the X chromosome in any EOC cell line. The absence of XIST expression is consistent with Barr body loss in TOV112D and TOV21G. The combined evidence is consistent with two proposed mechanisms to account for absence of Xi in female cancers: Xi loss followed by Xa duplication (exemplified by TOV112D) and transcriptional reactivation of Xi (exemplified by TOV21G). Despite an alteration in XIST expression and differences in allelic content in the EOC cell lines, the chromosome X transcriptome was modified modestly when compared with that of NOSE samples.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17143508

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  26 in total

Review 1.  Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery.

Authors:  Dawn M Carone; Jeanne B Lawrence
Journal:  Semin Cancer Biol       Date:  2012-06-18       Impact factor: 15.707

2.  Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer.

Authors:  Stacey J Winham; Nicholas B Larson; Sebastian M Armasu; Zachary C Fogarty; Melissa C Larson; Brian M McCauley; Chen Wang; Kate Lawrenson; Simon Gayther; Julie M Cunningham; Brooke L Fridley; Ellen L Goode
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

3.  Downregulation of BC200 in ovarian cancer contributes to cancer cell proliferation and chemoresistance to carboplatin.

Authors:  D I Wu; Tianzhen Wang; Chengcheng Ren; Lei Liu; Dan Kong; Xiaoming Jin; Xiaobo Li; Guangmei Zhang
Journal:  Oncol Lett       Date:  2015-12-01       Impact factor: 2.967

Review 4.  Expression and function of a large non-coding RNA gene XIST in human cancer.

Authors:  Sarah M Weakley; Hao Wang; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

Review 5.  Guided by RNAs: X-inactivation as a model for lncRNA function.

Authors:  John E Froberg; Lin Yang; Jeannie T Lee
Journal:  J Mol Biol       Date:  2013-06-28       Impact factor: 5.469

Review 6.  Sexual dimorphism in cancer.

Authors:  Andrea Clocchiatti; Elisa Cora; Yosra Zhang; G Paolo Dotto
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

7.  The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles.

Authors:  Michael C J Quinn; Daniel J Wilson; Fiona Young; Adam A Dempsey; Suzanna L Arcand; Ashley H Birch; Paulina M Wojnarowicz; Diane Provencher; Anne-Marie Mes-Masson; David Englert; Patricia N Tonin
Journal:  J Transl Med       Date:  2009-07-06       Impact factor: 5.531

8.  Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines.

Authors:  Neal Al Cody; Magdalena Zietarska; Ali Filali-Mouhim; Diane M Provencher; Anne-Marie Mes-Masson; Patricia N Tonin
Journal:  BMC Med Genomics       Date:  2008-08-07       Impact factor: 3.063

9.  BCoR-L1 variation and breast cancer.

Authors:  Felicity Lose; Jeremy Arnold; David B Young; Carolyn J Brown; Graham J Mann; Gulietta M Pupo; Kum Kum Khanna; Georgia Chenevix-Trench; Amanda B Spurdle
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Comparative proteome analysis of human epithelial ovarian cancer.

Authors:  Jean-Philippe Gagné; Chantal Ethier; Pierre Gagné; Geneviève Mercier; Marie-Eve Bonicalzi; Anne-Marie Mes-Masson; Arnaud Droit; Eric Winstall; Maxim Isabelle; Guy G Poirier
Journal:  Proteome Sci       Date:  2007-09-24       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.